Sea Cucumber Fucoidan Inhibits Helicobacter pylori Gastritis via MAPK/NF-κB Signaling and Gut Microbiota Modulation

Antibiotic-based eradication therapy forHelicobacter pylori faces challenges such as the increasing number of antibiotic-resistant strains and gut microbiota dysbiosis. The study evaluated the effects of fucoidan from sea cucumber cooking liquid (Fuc-SC) on Helicobacter pylori Sydney strain SS1 (Hp SS1)-associated gastritis. The backbone structure of Fuc-SC was composed of alternating -> 3)-alpha-L-Fucp-(1 -> 4)-alpha-L-Fucp-(1 -> linked fucose residues. The mouse experiments demonstrated that Fuc-SC reduced the colonization of Hp SS1 in the gastric mucosa through decreasing the level of urease, Hp-IgG, and CagA-IgG. In addition, Fuc-SC regulated oxidative stress levels by reducing NO, MDA, and ROS levels, while increasing the activity of SOD and GSH-Px. Compared to antibiotic treatment alone, the combination of Fuc-SC with antibiotics further enhanced the antioxidant effects. Molecular mechanisms indicated that Fuc-SC regulated the MAPK/NF-kappa B signaling pathway, downregulating the expression of inflammatory factors such as IL-1 beta and TNF-alpha and further modulating the expression of S100A8 and E-cadherin. Gut microbiota analysis indicated that Fuc-SC reversed the depletion of Lactobacillus caused by antibiotic treatment. Additionally, Fuc-SC significantly promoted the biosynthesis of microbial metabolites such as butyric acid, isobutyric acid, hexanoic acid, and phospholipids, thereby alleviating inflammation. These findings highlight its potential as a sustainable, nonantibiotic therapy for Helicobacter pylori-associated gastritis.